Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Care Res (Hoboken)
Autors principals: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Spondyloarthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://ncbi.nlm.nih.gov/pubmed/27696727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23092
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars